January 16, 2025
Article
Since 1968, CR&T is proud to have maintained our mission to fund research emphasizing the cause, prevention, treatment and cure of MPN.
FDA Approves Initiation of a New Trial in Recurrent Glioblastoma
The Benefit of Clinical Trial Enrollment for Patients With Cancer
Addressing Gaps, Challenges and Disparities in AYA Cancer Care
Unexpected Challenges 11 Years After Breast Cancer